There is a mixed opinion about this IPO. Some analyst suggested to apply for the IPO considering that Saamya Biotech has been issued at a reasonable price and the profile of the company is clean considering its directors and have said that people should subscribe with long term view in this IPO.
Finchimica, Spa Italy has 100% buying agreement with Saamya Biotech for anti-cancer drug which would be a fetching point for this company on the long term.
Others says it is not wise to invest in this IPO as the financial performance of this company is not great and in the post paid capital of the company the promoters stake would be only 7%.
Based on the above opinions you can give a miss to this IPO. If you are want to reap the benefit of extra ordinary gains which all IPO listing are giving and are willing to take risk then you may want to apply.
No comments:
Post a Comment